Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma
- PMID: 16166100
- PMCID: PMC1747263
- DOI: 10.1136/thx.2005.045260
Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma
Abstract
Background: Tumour necrosis factor alpha (TNFalpha) is a major therapeutic target in a range of chronic inflammatory disorders characterised by a Th1 type immune response in which TNFalpha is generated in excess. By contrast, asthma is regarded as a Th2 type disorder, especially when associated with atopy. However, as asthma becomes more severe and chronic, it adopts additional characteristics including corticosteroid refractoriness and involvement of neutrophils suggestive of an altered inflammatory profile towards a Th1 type response, incriminating cytokines such as TNFalpha.
Methods: TNFalpha levels in bronchoalveolar lavage (BAL) fluid of 26 healthy controls, 42 subjects with mild asthma and 20 with severe asthma were measured by immunoassay, and TNFalpha gene expression was determined in endobronchial biopsy specimens from 14 patients with mild asthma and 14 with severe asthma. The cellular localisation of TNFalpha was assessed by immunohistochemistry. An open label uncontrolled clinical study was then undertaken in 17 subjects with severe asthma to evaluate the effect of 12 weeks of treatment with the soluble TNFalpha receptor-IgG1Fc fusion protein, etanercept.
Results: TNFalpha levels in BAL fluid, TNFalpha gene expression and TNFalpha immunoreative cells were increased in subjects with severe corticosteroid dependent asthma. Etanercept treatment was associated with improvement in asthma symptoms, lung function, and bronchial hyperresponsiveness.
Conclusions: These findings may be of clinical significance in identifying TNFalpha as a new therapeutic target in subjects with severe asthma. The effects of anti-TNF treatment now require confirmation in placebo controlled studies.
Comment in
-
Etanercept in chronic severe asthma.Thorax. 2006 Jul;61(7):640; author reply 640. Thorax. 2006. PMID: 16807393 Free PMC article. No abstract available.
Similar articles
-
4-1 BB stimulation inhibits allergen-specific immunoglobulin E production and airway hyper-reactivity but partially suppresses bronchial eosinophilic inflammation in a mouse asthma model.Clin Exp Allergy. 2006 Mar;36(3):377-85. doi: 10.1111/j.1365-2222.2006.02445.x. Clin Exp Allergy. 2006. PMID: 16499650
-
Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.Eur J Pharmacol. 2006 Oct 10;547(1-3):125-35. doi: 10.1016/j.ejphar.2006.07.002. Epub 2006 Jul 13. Eur J Pharmacol. 2006. PMID: 16956605
-
Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.Scand J Rheumatol. 2008 May-Jun;37(3):173-8. doi: 10.1080/03009740801898608. Scand J Rheumatol. 2008. PMID: 18465450
-
[Role of tumor necrosis factor-alpha in allergic inflammation and airway hyperresponsiveness].Pol Merkur Lekarski. 2004 Feb;16(92):173-8. Pol Merkur Lekarski. 2004. PMID: 15176305 Review. Polish.
-
Agents against cytokine synthesis or receptors.Eur J Pharmacol. 2006 Mar 8;533(1-3):289-301. doi: 10.1016/j.ejphar.2005.12.046. Epub 2006 Feb 2. Eur J Pharmacol. 2006. PMID: 16457805 Review.
Cited by
-
Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series.Open Respir Med J. 2013;7:21-5. doi: 10.2174/1874306401307010021. Epub 2013 Feb 22. Open Respir Med J. 2013. PMID: 23526476 Free PMC article.
-
Tumour necrosis factor-alpha blockade suppresses murine allergic airways inflammation.Clin Exp Immunol. 2008 Jan;151(1):114-22. doi: 10.1111/j.1365-2249.2007.03509.x. Epub 2007 Oct 11. Clin Exp Immunol. 2008. PMID: 17931392 Free PMC article.
-
Contribution of systemic and airway immune responses to pediatric obesity-related asthma.Paediatr Respir Rev. 2021 Mar;37:3-9. doi: 10.1016/j.prrv.2020.02.005. Epub 2020 Mar 6. Paediatr Respir Rev. 2021. PMID: 32253127 Free PMC article. Review.
-
Protective Role of Eosinophils and TNFa after Ozone Inhalation.Res Rep Health Eff Inst. 2017 Mar;2017(191):1-41. Res Rep Health Eff Inst. 2017. PMID: 29659241 Free PMC article.
-
Mouse models of allergic asthma: acute and chronic allergen challenge.Dis Model Mech. 2008 Nov-Dec;1(4-5):213-20. doi: 10.1242/dmm.000323. Dis Model Mech. 2008. PMID: 19093027 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical